Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV

NCT02425111 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02425111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02425111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
March 30, 2015
Completion date
February 21, 2018
Enrollment
101 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease